MSMikołaj Stańko

Mikołaj Stańko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mikołaj Stańko has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond Weight Loss: Pleiotropic Effects of GLP-1 Receptor Agonists — A Narrative Review

    by Szymon Pieczara, Paulina Musiał, Wojciech Nowicki, Damian Machaj, Mikołaj Stańko, Zofia Stefanik, Piotr Urbanowicz

    Introduction and purpose. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, were introduced for glycaemic control and weight reduction, but a rapidly expanding body of evidence shows benefits that extend far beyond the scale. The purpose of this narrative review is to synthesise current evidence on the pleiotropic effects of GLP-1 RAs across cardiovascular, renal, hepatic, respiratory, neurological and addiction-related domains, and to examine the impact of these agents on body composition and the role of physical activity in preserving skeletal muscle. Description of the state of knowledge. Landmark randomised trials demonstrate reductions in major adverse cardiovascular events (SELECT, SUSTAIN-6, SOUL), slowed progression of chronic kidney disease (FLOW), resolution of metabolic dysfunction-associated steatohepatitis (ESSENCE) and marked improvement in obstructive sleep apnoea (SURMOUNT-OSA). These effects are only partly explained by weight loss and glucose lowering, implicating direct anti-inflammatory and tissue-protective mechanisms. A key limitation is that roughly one quarter of total weight lost is lean mass; evidence indicates that resistance and combined exercise can substantially attenuate this loss and preserve physical function. Summary. GLP-1 RAs have evolved into multi-organ cardiometabolic therapies. Combining pharmacotherapy with structured physical activity, particularly resistance training, appears essential to optimise the quality of weight loss and preserve muscle, linking pharmacology with exercise science. Keywords: Glucagon-Like Peptide-1 Receptor Agonists; Semaglutide; Tirzepatide; Exercise; Body Composition; Cardiovascular Diseases

  • Open Access

    Application of Artificial Intelligence in the Detection and Prediction of Atrial Fibrillation in ECG Recordings – A Narrative Review

    by Szymon Pieczara, Paulina Musiał, Wojciech Nowicki, Damian Machaj, Mikołaj Stańko, Zofia Stefanik, Piotr Urbanowicz

    Introduction and purpose. Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a leading cause of ischaemic stroke, yet it frequently remains undiagnosed because of its paroxysmal and often asymptomatic nature. Artificial intelligence (AI), and in particular deep learning applied to the electrocardiogram (ECG), has emerged as a transformative approach both for detecting AF when the arrhythmia is present and for predicting future AF from an ECG recorded during sinus rhythm. The purpose of this narrative review is to summarise the current state of knowledge on AI-enabled ECG analysis for the detection and prediction of AF and to critically appraise its clinical readiness. Description of the state of knowledge. Convolutional neural networks can classify AF on single-lead and twelve-lead ECG with cardiologist-level accuracy (area under the curve, AUC, above 0.97 for rhythm classification) and can identify an "electrocardiographic signature" of AF on a normal sinus-rhythm tracing (AUC approximately 0.87). Consumer wearables using photoplethysmography and single-lead ECG achieve pooled sensitivity and specificity around 95%. Predictive models for incident AF reach AUC values of 0.78–0.85 and have been validated prospectively, enriching the diagnostic yield of screening. Nevertheless, false positives, unclassifiable tracings, limited external validity, and the absence of trials demonstrating a reduction in stroke temper enthusiasm. Summary. AI-ECG is a mature and accurate tool for AF detection and a promising instrument for AF prediction, but its translation into improved patient-relevant outcomes remains unproven. Rigorous external validation, outcome-driven randomised trials, and clear regulatory and implementation frameworks are required before routine clinical adoption. Keywords: Atrial Fibrillation; Artificial Intelligence; Deep Learning; Electrocardiography; Mass Screening; Stroke

  • Open Access

    IMPACT OF ORAL MICROBIOME DYSBIOSIS ON THE RISK, PATHOGENESIS AND TREATMENT OF HEAD AND NECK CANCERS: A LITERATURE REVIEW

    by Paulina Musiał, Szymon Pieczara, Zofia Stefanik, Ewa Drzazga-Wilk, Mikołaj Stańko, Julia Smagowska, Wojciech Nowicki, Piotr Urbanowicz, Damian Machaj, Katarzyna Rekiel

    Background: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common malignancy worldwide and is associated with substantial morbidity and mortality. Although tobacco use, alcohol consumption, and human papillomavirus (HPV) infection remain the principal risk factors, growing evidence suggests that oral microbiome dysbiosis may contribute to tumor initiation, progression, and treatment response. Aim: This review summarizes current evidence linking oral microbiome dysbiosis with HNSCC, evaluates proposed biological mechanisms, and highlights major gaps requiring future investigation. Methods: A literature review was conducted by searching PubMed, Scopus, Web of Science, and Google Scholar for studies published through March 2026. Summary: Prospective cohort studies and case-control analyses have reported enrichment of periodontal-associated pathogens, including Fusobacterium nucleatum, Porphyromonas gingivalis, and Treponema denticola, in tumor tissues and saliva of patients with HNSCC, alongside depletion of commensal genera such as Streptococcus, Rothia, and Actinomyces. These organisms may influence carcinogenesis through NF-κB activation, Wnt/β-catenin signaling, epithelial–mesenchymal transition, apoptosis resistance, and immune modulation. Cancer therapies, particularly radiotherapy and chemotherapy, profoundly alter oral microbial communities and may worsen oral mucositis, candidiasis, and dental complications. Microbiome-targeted strategies, including probiotics, represent promising adjunctive approaches, although robust clinical validation is still required.

  • Open Access

    Inositols in PCOS/PMOS: therapeutic role, metabolic implications, and combination with metformin

    by Alicja Biskup, Agata WnęK, Julia Smagowska, Natalia Staszko, Ewa Kala-Kaziszyn, Kamila Bała, Mikołaj Stańko

    Polycystic Ovary Syndrome (PCOS), increasingly referred to as polyendocrine metabolic ovarian syndrome (PMOS), is a heterogeneous endocrine–metabolic disorder associated with reproductive dysfunction, hyperandrogenism, insulin resistance, and increased cardiometabolic risk. Due to the central role of insulin resistance, insulin-sensitizing therapies such as myo-inositol (MI), D-chiro-inositol (DCI), and metformin have gained growing clinical attention. Evidence from studies published between 2015 and 2026 suggests that MI and DCI may improve insulin sensitivity, hormonal balance, and reproductive outcomes, including menstrual cycle regularity and ovulation. The 40:1 MI/DCI ratio remains the most extensively studied formulation and appears to reflect physiological proportions. Metformin continues to play a key therapeutic role, particularly in women with insulin resistance, overweight, or obesity, while combination therapy with inositols may provide additional benefits in selected cases. However, evidence remains heterogeneous, highlighting the need for further high-quality randomized controlled trials to clarify the long-term efficacy and optimal clinical use of inositols in PCOS/PMOS management.

  • Open Access

    Biopsychosocial Pathways Linking Depression and Oral Health: A Literature Review

    by Zofia Stefanik, Mikołaj Stańko, Natalia Stefanik, Julia Smagowska, Paulina Musiał, Szymon Pieczara, Jakub Pastuszka, Julia Wilk

    Background. Despite their high global prevalence, depression and oral diseases are rarely addressed within a unified clinical framework. Recent evidence highlights a bidirectional relationship with overlapping biological and behavioral underpinnings.Aim. This review consolidates current knowledge on the mutual influence of depression and oral health and explores the underlying mechanisms.Methods. A structured search of PubMed/MEDLINE, EMBASE, PsycINFO, and the Cochrane Library identified systematic reviews, meta-analyses, observational, and mechanistic studies published between 2016 and 2025.Results. Depression is consistently linked to caries, periodontitis, tooth loss, and xerostomia, while periodontal inflammation may contribute to depressive symptomatology. Underlying mechanisms span neuroendocrine, immune, microbial, behavioral, pharmacological, and psychosocial domains. Conclusions. Recognizing depression and oral disease as mutually reinforcing conditions supports the case for integrated, interdisciplinary care models that incorporate routine cross-screening.